April 8-13, 2022
BioLexis is pleased to announce the acceptance of a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022. Representing BioLexis, Co-Founder and Chief Scientific Officer, Dr. Hariprasad Vankayalapati will present data highlighting an orally available, CDK9 selective small molecule inhibitor demonstrating early proof of concept in n-Myc-driven neuroendocrine prostate cancers (NEPC). Dr. Vankayalapati noted “Development of CDK9 selective drugs for cancer applications have been pursued globally for several decades. This is the first reported data demonstrating this level of selectivity.”
Headquartered in American Fork, Utah, BioLexis has created an AI-driven drug discovery platform they dubbed MolecuLern. Based on more than two decades of pioneering research by Dr. Vankayalapati and his co-founder, Dr. David Bearss, MolecuLern leverages a vast proprietary compound library coupled with AI software developed by BioLexis. The combination of unique tools allows BioLexis to reduce the typical time to identify a potential drug from several years to just four weeks.
“This is another in a series of impressive discoveries using the MolecuLern platform” stated Dr. David Bearss, CEO of BioLexis. “While we are focused on bringing a select number of assets to the clinic, we see MolecuLern as a tremendous opportunity to partner assets we’ve discovered as well as provide unique discovery and development services to the pharmaceutical industry.”
To date, MolecuLern has established an 80% success rate in identifying drug candidates. BioLexis will begin partnering with the MolecuLern platform in 2023, following completion of validation studies.
Biolexis Therapeutics is a privately held biopharmaceutical company dedicated to developing small molecules targeting complex disease processes. Biolexis rapidly discovers and develops novel clinical candidates with unprecedented speed and accuracy through their proprietary MolecuLern AI-enabled drug discovery process.
The American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. Founded in 1907, by a few scientists gathering to share information to the multifaceted organization that exists today, the growth of the AACR reflects the increasing complexity of our understanding of the collection of devastating diseases we now know as cancer.